Ernexa Therapeutics Inc. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Compensated Absences
Ernexa Therapeutics Inc. (ERNA) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Compensated Absences of $3.00 thousand as of 2023-12-31, per its 10-K filed 2024-03-14.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense › Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences · last filed 2024-03-14
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Compensated Absences $3.00K.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Compensated Absences $81.00K.
- 2021-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Compensated Absences $30.00K.
- 2020-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Compensated Absences $0.00.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Compensated Absences |
|---|---|
| 2023-12-31 | $3.00K 10-K · filed 2024-03-14 |
| 2022-12-31 | $81.00K 10-K · filed 2024-03-14 |
| 2021-12-31 | $30.00K 10-K · filed 2023-03-20 |
| 2020-12-31 | $0.00 10-K/A · filed 2022-07-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |